Technical Advantages: Its independently developed biological 3D printers account for nearly 60% of the domestic market and are exported to over 150 countries and regions worldwide. They have supported the publication of hundreds of papers in top journals such as Nature. Its core technology, "Discrete Manufacturing Micro-Computed Tomography (MCT)", enables real-time quality control during the printing process with micron-level precision, and has been supported by the National Key R&D Program.
Application Fields: It has completed dozens of surgeries in clinical scenarios such as cartilage repair and skin regeneration, and established joint laboratories with multiple top tertiary hospitals.
Official Website: www.regenovo.com
Technical Accumulation: Ranked second among domestic enterprises with 280 biological 3D printing patents, its core "Bio-Brick" technology can construct vascularized tissues, and multiple animal experiments have been completed in the field of bone defect repair.
Industrial Layout: It has established a translational medicine center in collaboration with West China Hospital of Sichuan University, promoting products such as 3D-printed artificial corneas into the clinical trial stage.
Official Website: www.innobiomed.com
Market Position: The world's first synthetic dura mater (ReDura®) has been approved for marketing, with cumulative application in over 650,000 surgeries. Its 3D-printed nerve conduit (ReNerve®) fills the domestic gap and breaks the monopoly of AxoGen (USA).
R&D Investment: Annual R&D expenditure accounts for over 25% of revenue. It has established cooperation with pharmaceutical companies such as AstraZeneca in the field of organoid chips.
Official Website: www.medprin.com
Technical Features: Integrating cell therapy with 3D printing technology, it has developed porous scaffolds capable of loading mesenchymal stem cells, and completed animal model verification in the field of liver fibrosis treatment.
Production Capacity: It has built GMP-level biomaterial production lines in Shanghai and Wuhan, with an annual capacity of 500,000 implants.
Official Website: www.sinocelltech.com
Clinical Breakthrough: The world's first 3D-printed meniscus repair system has been approved by NMPA, achieving a 1-year survival rate of over 90% in the treatment of knee joint injuries. Its "printing-implantation integration" technology has been included in the Clinical Application Guidelines for Orthopedic 3D Printing Technology.
International Cooperation: It has jointly developed a metal-biological composite material printing platform with EOS (Germany) for the production of customized orthopedic implants.
Official Website: www.novamedicaltech.com
Equipment Innovation: Launched the world's first 10μm-level micro-nano biological 3D printing system (nanoArch® S140 BIO), which can print complex vascular networks containing living cells with a cell survival rate exceeding 95%.
Material R&D: The methacrylated gelatin (GelMA) ink developed in cooperation with Suling Technology matches the mechanical properties of natural cartilage and has been used in cardiovascular tissue engineering research.
Official Website: www.b9c.com
Clinical Translation: The world's first "biological 3D printing gun" has entered Phase II clinical trials, achieving cartilage regeneration through arthroscopic injection of photosensitive hydrogel, with follow-up of 50 cases completed at Shanghai Ninth People's Hospital.
Technical Barriers: It holds patents for 12 biological ink formulations, capable of printing bionic structures covering 90% of human tissue types, with controllable material degradation cycles ranging from 3 to 12 months.
Official Website: www.huaxiasiyin.com
Equipment Matrix: Launched a multi-nozzle biological 3D printing system (Bio-Architect X) supporting multi-material co-printing, accounting for 30% of the domestic market in drug screening microfluidic chips.
Industry Standards: Led the formulation of Technical Review Guidelines for Registration of Biological 3D Printing Medical Devices, promoting the standardized development of the industry.
Official Website: www.3d-print.com.cn
Technology Output: Provided scientific research-grade biological 3D printing equipment to Tsinghua University, Zhejiang University, etc., supporting their publication of artificial heart research results in Science.
International Certification: Its biological printing equipment has passed CE certification, exported to 12 European countries, and established cooperation with Straumann (Switzerland) in the field of dental implants.
Official Website: www.altair-tech.com
Cross-innovation: Expanded metal 3D printing technology to the biomedical field, developing a titanium alloy porous trabecular bone structure with a porosity of 85% and mechanical properties matching cancellous bone.
Military Background: Relying on technical resources from Northwestern Polytechnical University, it has obtained clinical verification from the PLA General Hospital in the field of skull repair.
Official Website: www.blt3d.com